Akso Health Group Sponsored ADR
AHG Healthcare Medical Distribution
Akso Health Group Sponsored ADR’s revenue for fiscal 2026 (year ended March 2026) was $13.8 million, down 6.40% from fiscal 2025.
Follow AHG
Akso Health Group Sponsored ADR (AHG) EV/Sales
As of 16 October 2026, Akso Health Group Sponsored ADR (AHG) trades at a EV/Sales of 1.8×. Over the past ten years it has ranged from −2.7× (December 2024) to 47.8× (October 2021); the current reading is higher than 49% of that period. That is above the Medical Distribution industry median of 0.6× and below the Healthcare sector median of 3.4×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2026 | 2.5× | — |
| FY2025 | −2.4× | — |
| FY2024 | 1.5× | 55.99% |
| FY2023 | 1.0× | (70.85%) |
| FY2022 | 3.3× | 7.42% |
| FY2021 | 3.1× | 80.47% |
| FY2020 | 1.7× | (17.17%) |
| FY2019 | 2.0× | (42.57%) |
| FY2018 | 3.6× | — |
| FY2017 | 0.0× | — |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Sep 2023 | 1.7× | 5.29% |
| Mar 2023 | 1.7× | (28.28%) |
| Sep 2022 | 2.3× | (62.01%) |
| Mar 2022 | 6.1× | (26.95%) |
| 14 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| HKPD Cellyan Biotechnology Co., Ltd compare | n/m |
| YI 111, Inc. Sponsored ADR compare | 0.0× |
| COR Cencora, Inc. compare | 0.2× |
| CAH Cardinal Health, Inc. compare | 0.3× |
| COSM Cosmos Health Inc. compare | 0.4× |
| ACH Accendra Health, Inc. compare | 0.9× |
| HSIC Henry Schein, Inc. compare | 0.9× |
| AHG Akso Health Group Sponsored ADR | 1.8× |
| FOCL FocalTherics compare | 2.1× |
| Medical Distribution industry median | 0.6× |
| Healthcare sector median | 3.4× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)